Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Parkinson disease and Alzheimer disease: environmental risk factors.

Campdelacreu J.

Neurologia. 2014 Nov-Dec;29(9):541-9. doi: 10.1016/j.nrl.2012.04.001. Epub 2012 Jun 14. Review. English, Spanish.

2.

Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial.

Schenkman M, Hall DA, Barón AE, Schwartz RS, Mettler P, Kohrt WM.

Phys Ther. 2012 Nov;92(11):1395-410. doi: 10.2522/ptj.20110472. Epub 2012 Jul 19.

3.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group..

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

4.

Genetics of Parkinson disease and other movement disorders.

Kumar KR, Lohmann K, Klein C.

Curr Opin Neurol. 2012 Aug;25(4):466-74. doi: 10.1097/WCO.0b013e3283547627. Review.

PMID:
22772876
5.

Caffeine for treatment of Parkinson disease: a randomized controlled trial.

Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B.

Neurology. 2012 Aug 14;79(7):651-8. doi: 10.1212/WNL.0b013e318263570d. Epub 2012 Aug 1. Erratum in: Neurology. 2012 Oct 16;79(16):1744.

6.

Updates in the medical management of Parkinson disease.

Fernandez HH.

Cleve Clin J Med. 2012 Jan;79(1):28-35. doi: 10.3949/ccjm.78gr.11005. Review.

7.

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group..

Neurology. 2012 Jul 3;79(1):55-65. doi: 10.1212/WNL.0b013e31825dcdc1. Epub 2012 Jun 20.

8.

Meta-analysis of early nonmotor features and risk factors for Parkinson disease.

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A.

Ann Neurol. 2012 Dec;72(6):893-901. doi: 10.1002/ana.23687. Epub 2012 Oct 15. Review.

9.

Managing the patient with newly diagnosed Parkinson disease.

Singer C.

Cleve Clin J Med. 2012 Jul;79 Suppl 2:S3-7. doi: 10.3949/ccjm.79.s2a.01. Review.

10.

Parkinson disease.

Park NH.

JAAPA. 2012 May;25(5):73-4. Review. No abstract available.

PMID:
22712157
11.

Olfactory dysfunction in Parkinson disease.

Doty RL.

Nat Rev Neurol. 2012 May 15;8(6):329-39. doi: 10.1038/nrneurol.2012.80. Review.

PMID:
22584158
12.

Does vigorous exercise have a neuroprotective effect in Parkinson disease?

Ahlskog JE.

Neurology. 2011 Jul 19;77(3):288-94. doi: 10.1212/WNL.0b013e318225ab66. Review.

13.

Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.

Tarsy D.

JAMA. 2012 Jun 6;307(21):2305-14. doi: 10.1001/jama.2012.4829.

PMID:
22706836
14.

Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies.

Lopes FM, Schröder R, da Frota ML Jr, Zanotto-Filho A, Müller CB, Pires AS, Meurer RT, Colpo GD, Gelain DP, Kapczinski F, Moreira JC, Fernandes Mda C, Klamt F.

Brain Res. 2010 Jun 14;1337:85-94. doi: 10.1016/j.brainres.2010.03.102. Epub 2010 Apr 7.

PMID:
20380819
15.

Large-scale replication and heterogeneity in Parkinson disease genetic loci.

Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEO-PD Consortium..

Neurology. 2012 Aug 14;79(7):659-67. doi: 10.1212/WNL.0b013e318264e353. Epub 2012 Jul 11.

16.

Treadmill training for individuals with Parkinson disease.

Earhart GM, Williams AJ.

Phys Ther. 2012 Jul;92(7):893-7. doi: 10.2522/ptj.20110471. Epub 2012 Apr 26. No abstract available.

17.

Late-stage Parkinson disease.

Coelho M, Ferreira JJ.

Nat Rev Neurol. 2012 Aug;8(8):435-42. doi: 10.1038/nrneurol.2012.126. Epub 2012 Jul 10. Review.

PMID:
22777251
18.

Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease.

Shulman LM, Katzel LI, Ivey FM, Sorkin JD, Favors K, Anderson KE, Smith BA, Reich SG, Weiner WJ, Macko RF.

JAMA Neurol. 2013 Feb;70(2):183-90. doi: 10.1001/jamaneurol.2013.646.

19.

Caffeine intake, smoking, and risk of Parkinson disease in men and women.

Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, Hollenbeck AR, Blair A, Chen H.

Am J Epidemiol. 2012 Jun 1;175(11):1200-7. doi: 10.1093/aje/kwr451. Epub 2012 Apr 13.

20.

Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease.

Rousseaux MW, Marcogliese PC, Qu D, Hewitt SJ, Seang S, Kim RH, Slack RS, Schlossmacher MG, Lagace DC, Mak TW, Park DS.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15918-23. Epub 2012 Sep 10. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11212.

Supplemental Content

Support Center